Skip to content

IDEAYA Biosciences

US · IDYA #2357 by market cap Listed 2019
25.56 -0.61 -2.33%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 25.81 -1.38%
After-hours 25.56 0.00%
42.4825.5625.562026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on IDYA?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is -28.8% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 8.5% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days C → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 02:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C+

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D

How much profit the business keeps from each dollar of sales and capital.

Operating margin -72.8% Better than 8%
Net margin -52.0% Better than 9%
Return on equity -10.9% Better than 19%
Return on invested capital -15.0% Better than 15%
Momentum C-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -35.6% Better than 13%
6-month return -12.2% Better than 37%
12-month return (ex latest month) 2.1% Better than 37%
Distance below 52-week high 40.1% Better than 28%
Financial Health A+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 11.3x Better than 94%
Debt to assets 2.5% Better than 86%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 107.0% Better than 85%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -19.70%
1M -27.71%
3M -34.65%
6M -13.79%
YTD -26.06%
1Y -22.92%
3Y -17.07%
5Y +10.08%

Key statistics

Price & volume

Prev close
26.17
Open
25.83
Day range
25.46 - 26.87
Avg price
25.78
Volume
1.11M
Turnover
28.72M
Amplitude
5.40%
52-week range
25.46 - 42.68

Valuation

P/E
-19.97
P/E (TTM)
-5.68
P/B
2.26
EPS
-1.28
Net profit
-123.77M
Net assets
1.09B

Share structure

Market cap
2.47B
Float cap
2.32B
Shares out
96.69M
Float shares
90.84M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2019-05-23
52-week range 1% of range
25.46 42.68

40.1% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-21.57M net over the window

Short interest

Shares short
8.24M
As of
2026-10-30

Frequently asked questions

What is the current stock price of IDEAYA Biosciences (IDYA)?

IDEAYA Biosciences last traded at 25.56. This page shows a periodic quote snapshot. Check the displayed quote time.

What is IDEAYA Biosciences's market cap?

About 2.47B.

What is the P/E ratio of IDEAYA Biosciences?

The trailing twelve-month P/E is -5.68. The Valuation tab shows it against the stock's own five-year range.

Does IDEAYA Biosciences pay a dividend?

IDEAYA Biosciences does not currently pay a regular dividend.

Is IDEAYA Biosciences a buy according to analysts?

The consensus of 11 analysts is a Buy rating, with an average 12-month price target of 52.90, which implies 107.0% upside from the current price. This is not investment advice.

What is IDEAYA Biosciences's StockVane Quant Rating?

The StockVane Momentum strategy currently rates IDEAYA Biosciences a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

IDEAYA Biosciences discussion 0 comments

Add a comment